This gap in research presents a compelling opportunity to investigate whether PF's cardioprotective effects mirror those of other GLP‐1 receptor agonists, potentially offering a new therapeutic avenue for cardiovascular diseases. This evidence concerns the gene GLP1R and cardiovascular disorder.